An update on the management of hepatitis C virus-related arthritis

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 14, 2014, Pages 2039-2045

  Palazzi, Carlo ^a,b   D'Amico, Emilio ^c   D'Angelo, Salvatore ^a   Gilio, Michele ^a   Leccese, Pietro ^a   Olivieri, Ignazio ^a  

^a SAN CARLO HOSPITAL   (Italy)

^b Ospedale Madonna Delle Grazie   (Italy)

^c SPIRITO SANTO HOSPITAL   (Italy)

Author keywords

Arthritis; Hepatitis C virus; Therapy; Treatment

Indexed keywords

BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; NONSTEROID ANTIINFLAMMATORY AGENT; ALPHA INTERFERON; ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTHRITIS; COCHRANE LIBRARY; EMBASE; HEPATITIS C VIRUS; HEPATITIS C VIRUS RELATED ARTHRITIS; HUMAN; MEDLINE; REVIEW; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; DISEASE MANAGEMENT; DRUG COMBINATION; HEPACIVIRUS; IMMUNOLOGY; VIROLOGY;

ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; ARTHRITIS; AUTOIMMUNE DISEASES; CYCLOSPORINE; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HUMANS; HYDROXYCHLOROQUINE; INTERFERON-ALPHA; RIBAVIRIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907047823     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.946404     Document Type: Review

References (54)

1. Antonelli A, Ferri C, Galeazzi M, et al. HCV infection: pathogenesis, clinical manifestations and therapy. Clin Exp Rheumatol 2008;26(Suppl 48):S39-47.
2. Rosa D, Saletti G, De Gregorio E, et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci USA 2005;102:18544-9
3. Calvaruso V, Crax A. Immunological alterations in hepatitis C virus infection. World J Gastroenterol 2013;19:8916-23
4. Palazzi C, Buskila D, D'Angelo S, et al. Autoantibodies in patients with chronic hepatitis C virus infection: pitfalls for the diagnosis of rheumatic diseases. Autoimmun Rev 2012;11:659-63
5. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 1999;42:2204-12
6. Iagnocco A, Coari G, Mammarella A, et al. Joint sonography in asymptomatic patients with HCV correlated hepatitis. Clin Exp Rheumatol 2004;22:43-8
7. Buskila D, Shnaider A, Neumann L, et al. Musculoskeletal manifestations and aut oantibody profile in 90 hepatitis C virus infected Israeli patients. Semin Arthritis Rheum 1998;28:107-13
8. Palazzi C,Olivieri I,D'Amico E,et al, Difficulties in the differential diagnosis be tween primitive rheumatic diseases and hepatitis C virus-related disorders, Clin Exp Rheumatol, 2005, 23, 2-6.
9. D'Amico E, Palazzi C, Fratelli V, et al. High prevalence of HCV infection in patients with rheumatoid arthritis. J Clin Rheumatol 1996;2:234-5
10. Rivera J, Garcí a-Monforte A, Pineda A, et al. Arthritis in patients with chronic hepatitis C virus infection. J Rheumatol 1999;26:420-4
11. Zuckerman E, Keren D, Rozembaum M, et al. Hepatitis C virus related arthritis: characteristics and response to therapy with interferon alpha. Clin Exp Rheumatol 2000;18:579-84
12. Fadda P, La Civita L, Zignego AL, et al. Studio clinico-sierologico dell'artrite in pazienti con e senza sindrome crioglobulinemica. Reumatismo 2002;54:316-23
13. Lovy MR, Starkebaum G, Uberoi S. Hepatitis C infection presenting with rheumatic manifestations: a mimic of rheumatoid arthritis. J Rheumatol 1996;23:979-83
14. Olivieri I, Palazzi C, Pa dula A. Hepatitis C virus infection and arthritis. Rheum Dis Clin North Am 2003;29:111-22
15. Rosner I, Rozenbaum M, Toubi E, et al. The case for hepatitis C arthritis. Semin Arthritis Rheum 2004;33:375-87
16. Zuckerman E, Yeshurun D, Rosner I. Management of hepatitis C virus related arthritis. BioDrugs 2001;15:573-84
17. Bassyouni IH, Ezz at Y, Hamdy S, et al. Clinical significance of anticyclic citrullinated peptide antibodies in Egyptian patients with chronic hepatitis C virus genotype IV infection. Clin Chem Lab Med 2009;47:842-7
18. Riccio A, Postiglione L, La Dogana P, et al. Anticyclic citrullinated peptide antibodies in patients affected by HCV-related arthritis. J Biol Regul Homeost Agents 2008;22:57-61
19. Sene D, Ghillani-Dalbin P, Limal N, et al. Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjogren's syndrome. Ann Rheum Dis 2006;65:394-7
20. Bombardieri M, Alessandri C, Labbadia G, et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infectionassociated polyart icular involvement. Arthritis Res Ther 2004;6:R137-41
21. Orge E, Cefle A, Yazici A, et al. The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients wi th chronic hepatitis C infection. Rheumatol Int 2010;30:485-8
22. Liu FC, Chao YC, Hou TY, et al. Usefulness of anti-CCP antibodies in patients with hepatitis C virus infection with or without a rthritis, rheumatoid factor, or cryoglobulinemia. Clin Rheumatol 2008;27:463-7
23. Wener MH, Hutchinson K, Morishima C, et al. Absence of antibodies to cyclic citrullinated peptide in sera of pat ients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum 2004;50:2305-8
24. Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serol ogic features and survival in 231 patients. Semin Arthritis Rheum 2004;33:355-74
25. Palazzi C, Olivieri I, D'Amico E, et al. Hepatitis C virus in psoriatic arthritis. Arthritis Rheum 2005;53:223-5
26. Palazzi C, Olivieri I, D'Amico E, et al. Treatment of HCV-related arthritis. Expert Opin Pharmacother 2005;6:27-34
27. Palazzi C, D'Angelo S , Olivieri I. Hepatitis C virus-related arthritis. Autoimmun Rev 2008;8:48-51
28. Manoukian AV, Carson JL. Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention. Drug Saf 1996;15:64-71
29. Teho NC, Farrel GC. Hepatotoxicity associated with non-steroidal antiinflammatory drugs. Clin Liver Dis 2003;7:401-13
30. Anelli MG,Scioscia C,Grattagliano,et al, Old and new antirheumatic drugs and the risk of hepatotoxicity, Ther Drug Monit, 2012, 34, 622-8.
31. Maddrey WC, Maurath CJ, Verburg KM, et al. The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am J Ther 2000;7:153-8
32. De Ledinghen V, Heresbach D, Fourdan et al. Anti-inflammatory drugs and variceal bleeding: a case-control study. Gut 1999;44:270-3
33. Lee YC, Chang CH, Lin JW, et al. Non-st eroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. Liver Int 2012;32:859-66
34. Magy N, Cribier B, Schmitt C, et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol 1999;21:253-61
35. Iannone F, La Montagna G, Bagnato G, et al. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepa titis C virus infection: a multicenter randomized clinical trial. J Rheumatol 2014;41:286-92
36. Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford) 2005;44:1016-20
37. Kujawska A, Clements M, Wise CM, et al. Hepatitis C and methotrexate. Arthritis Rheum 2003;49:843-5
38. Bathon JM, Cohen SB. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drug s in rheumatoid arthritis: where the rubber meets the road. Arthritis Rheum 2008;59:757-9
39. Nag A, Robotham JM, Tang H. Suppression of viral RNA binding and the assembly of infectious particles in vitro by cyclophilin inhibitors. J Virol 2012;86:12616-24
40. Watashi K, Shimotohno K. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti hepatitis C virus strategy. Rev Med Virol 2007;17:245-52
41. Iashii N, Watashi K, Hishiki T, et al. Diverse effects of cyclosporine on hepatitis C virus on hepatitis C virus strain replication. J Virol 2006;80:4510-20
42. El-Farrash MA, Aly HH, Watashi K, et al. In vitro infection of immortalized primary hepatocytes by HCV genotype 4a and inhibition of virus replication by cyclosporin. Microbiol Immunol 2007;51:127-33.
43. Giannitti C, Benucci M, Caporali R, et al. Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection. Int J Imm unopathol Pharmacol 2009;22:543-6
44. Cavazzana I, Ceribelli A, Cattaneo R, et al. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. A utoimmun Rev 2008;8:104-6
45. Bellisai F, Giannitti C, Donvito A, et al. Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepa titis C virus infection. Clin Rheumatol 2007;26:1127-9
46. Galeazzi M, Bellisai F, Giannitti C, et al. Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann N Y A cad Sci 2007;1110:544-9
47. Galeazzi M, Bellisai F, Manganelli S, et al. Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients. Autoimmun Rev 2006;5:493-8
48. Brunasso AM, Puntoni M, Gulia A, et al. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 2011;50:17 00-11
49. Bredemeier M, de Oliveira FK, Rocha CM. Low versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2014;66:228-35
50. Leandro MJ, Becerra-Fernandez E. B-cell therapies in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2011;25:535-48
51. De Vita S,Quartuccio L,Isola M,et al, A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis, Arthritis Rheum, 2012, 64, 843-53.
52. Sagnelli E, Pisaturo M, Sagnelli C, et al. Rituximab-based treatment, HCV replication, and hepatic flares. Clin Dev Immunol 2012;2012:945950
53. Delemos AS, Chung RT. Hepatitis C treatment: an incipient therapeutic revolution. Trends Mol Med 2014;20(6):315-21
54. Conteduca V, Sansonno D, Russi S, et al. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. J Infect 2014;68:1-20